Survodutide SUR
GCGR · GLP-1R dual agonist
Synthetic dual glucagon and GLP-1 receptor agonist studied in energy expenditure and hepatic fat metabolism research.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GCGR · GLP-1R dual agonist
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- SUR
- Development and regulatory status
- Investigational, phase 3 results reported; not approved
What researchers study
Survodutide is a synthetic peptide that activates both the glucagon and GLP-1 receptors. The glucagon component is of research interest for its links to energy expenditure and hepatic fat metabolism.
Research areas
- Glucagon and GLP-1 co-agonism in metabolic models
- Liver fat and hepatic metabolism studies
- Energy expenditure and body-weight research
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 2 trial
In 387 adults without diabetes, mean weight change at 46 weeks was -14.9% in the highest-dose group versus -2.8% with placebo
- phase 3 trial
In SYNCHRONIZE-1 (725 adults without diabetes), mean weight change at 76 weeks was -12.2% and -13.0% in two dose groups versus -5.4% with placebo
- phase 2 trial
In phase 2, gastrointestinal events were reported in 75% of survodutide recipients versus 42% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Mazdutideanother dual GLP-1 and glucagon receptor agonist for comparison
- Retatrutidetriple agonist that also includes glucagon-receptor activity
- Cagrilintideamylin pathway complementary to glucagon and GLP-1 signalling
